From OpenWetWare
Jump to navigationJump to search
172 bytes removed ,  13:06, 22 April 2011
no edit summary
[[Image:Wilke_newsicon_05202009.png|left|150px]] The spectrum of anti-HIV drugs was recently extended by a new class of drugs, the integrase inhibitors. The first drug of this class that received FDA approval is Raltegravir. Clinical data show that when previously untreated patients start treatment on Raltegravir, their viral load declines more rapidly than it does in patients who take instead the reverse-transcriptase inhibitor Efavirenz. This spring, Antiviral Therapy published a modeling study by [ Sedaghat et al.] that discusses the possible mechanisms responsible for this accelerated decline in viral load. The study argues that the accelerated decline is likely not caused by greater antiviral efficiency of Raltegravir compared to Efavirenz. Instead, because Raltegravir acts later in the viral life cycle than Efavirenz, at the beginning of Raltegravir therapy fewer cells have progressed to a state where the drug can not inhibit virus production, and hence the viral load declines faster. The study is a follow-up to a paper published in 2008 in [ Proc. Natl. Acad. Sci. USA].
= References =
#Brennan_et_al_2009 pmid=19535437
#Zhou_et_al_2009 pmid=19349643
#Sedaghat_et_al_2009a pmid=19430101
#Sedaghat_et_al_2008b pmid=18362342

Navigation menu